On July 17, 2025 Triore, a biopharmaceutical company developing new drugs, reported that it has completed a Series B investment round worth 22.5 billion won. This is considered a significant achievement amidst dampened investment sentiment across the bio-healthcare sector.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
In this Series B round, Woori Venture Partners, Shinhan Venture Investment, Hyundai Technology Investment, Regent Partners, and Sneak Peek Investment participated as new investors. IMM Investment, LSK Investment, KB Investment, Kiwoom Investment, Shinhan Capital, and Jin & Investment Partners, who participated in the previous Pre-Series A and Series A rounds, made follow-up investments. With this, Triore’s cumulative investment raised has exceeded 41.5 billion KRW. As Corporate Venture Capital (CVC) firms are currently reviewing investments based on collaboration with the business unit, the total investment scale is likely to expand.
Triore is developing ‘TROCAD’, a unique antibody platform capable of improving the therapeutic index of antibody-based therapies, and ‘TROSIG’, a novel Linker-Toxin system that enhances the drug stability and therapeutic efficacy of ADCs (Antibody-Drug Conjugates). The company presented its technology and pipeline at BioUS 2025, held in Boston last June, and these technologies were recognized as innovative solutions capable of overcoming the limitations of existing antibody and ADC therapies.
Triore has accumulated various achievements since its founding in 2021. In 2023, it was selected as a ‘Baby Unicorn’ company by the Ministry of SMEs and Startups. In the same year, it won the ‘Seoul-BMS Innovation2 Challenge’ and moved into the Seoul Biohub. Subsequently, it was selected as a ‘D-Unicorn’ company in 2024.
Cheon Ji-woong, Managing Director at Woori Venture Partners, a new investor, stated, "Triore is a biotech with the potential to establish itself as a game changer that transcends the limitations of existing treatments in the antibody and ADC fields," adding, "We have high expectations for Triore’s technology as a platform that can advance the ADC sector."
Woo Seong-ho, CEO of Triore, stated, "This investment round is the result of comprehensive recognition of Triore’s technological innovation, scientific expertise, and market potential." He added, "We plan to focus on R&D to validate the effectiveness of our platform technology based on the funds raised." He further remarked, "Ultimately, we will concentrate our capabilities to achieve major results, such as collaborations with global pharmaceutical companies, technology transfers, and expansion into overseas clinical trials."
Triore plans to accelerate the preclinical and clinical entry of next-generation ADC drug candidates utilizing the TROCAD and TROSIG platforms, while also expanding new partnerships and intensifying its efforts to target the global market.
(Press release, TriOar Biotechnology, JUL 17, 2025, View Source;idx=9 [SID1234664815])